A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

Gemici, Aliihsan; ÖZKALEMKAŞ, FAHİR; Dogu, Mehmet; Tekinalp, Atakan; ALACACIOĞLU, İNCİ; Guney, Tekin; Ince, Idris; GEDÜK, AYFER; ÇAĞLIYAN, GÜLSÜM; Maral, Senem; Serin, Istemi; GÜNDÜZ, EREN; Karakus, Volkan; Bekoz, Huseyin; Eren, Rafet; PINAR, İBRAHİM; Gunes, Ahmet; Sargin, Fatma; Sevindik, Omur

doi:10.1016/j.clml.2021.04.004

A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

Gemici A., ÖZKALEMKAŞ F., Dogu M. H., Tekinalp A., ALACACIOĞLU İ., Guney T., ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.21, no.8, 2021 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 21 Issue: 8
Publication Date: 2021
Doi Number: 10.1016/j.clml.2021.04.004
Journal Name: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Keywords: Bcl2, Inhibitor, Venetoclax, Acute myeloid leukemia, Real life, LOW-DOSE CYTARABINE, OLDER PATIENTS, BCL-2 INHIBITION, AZACITIDINE, SURVIVAL, CARE, AML
Bursa Uludag University Affiliated: Yes

Abstract

Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients with a median age of 67 years from different centers were included in the final analysis. Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.